STELARA Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving STELARA Growth

1. Blockbuster Global Sales Across Multiple Indications

STELARA generated approximately $10.36 billion in worldwide sales in 2024, including about $6.72 billion in U.S. revenue, despite increasing biosimilar competition in Europe.

The drug has consistently ranked among the top immunology brands globally and remains a major contributor to Johnson & Johnson's Innovative Medicine division.

2. Broad Label Across High-Prevalence Autoimmune Diseases

STELARA is approved for:

• Plaque psoriasis
• Psoriatic arthritis
• Crohn's disease
• Ulcerative colitis
• Pediatric plaque psoriasis and psoriatic arthritis

This broad multi-specialty presence has enabled strong uptake across dermatology, rheumatology, and gastroenterology practices. The expanding inflammatory bowel disease (IBD) market particularly accelerated STELARA's long-term growth trajectory.

3. Differentiated IL-12/23 Mechanism and Durable Efficacy

STELARA was among the first biologics to successfully target the IL-12/23 inflammatory pathway, helping establish the IL-23 class as a cornerstone of immune-mediated disease treatment.

Long-term clinical studies published in PubMed and major gastroenterology journals demonstrated durable remission rates and sustained mucosal healing in Crohn's disease and ulcerative colitis patients, supporting continued physician confidence and long treatment persistence.

Its efficacy combined with relatively convenient dosing (every 8-12 weeks maintenance) became a major commercial advantage over older biologics requiring more frequent administration.

4. Strong Safety and Physician Familiarity Built Over More Than a Decade

STELARA's long-term real-world safety profile has been a major driver of continued prescribing. Physicians often favor therapies with extensive post-marketing experience in chronic diseases requiring lifelong management.

The drug's comparatively favorable infection and malignancy profile versus some systemic immunosuppressants and JAK inhibitors supported adoption in both biologic-naive and biologic-experienced patients.

Real-world physician discussions and investor commentary frequently highlighted STELARA as a "trusted maintenance biologic" in chronic IBD management.

STELARA Recent Developments

• In April 2026, the US Food and Drug Administration (FDA) approved STELARA (ustekinumab) for the treatment of patients two years and older with moderately to severely active Crohn's disease (CD).

"STELARA Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of STELARA for approved indication like Crohn's disease, Plaque psoriasis, Psoriasis, Psoriatic arthritis, and Ulcerative colitis; as well as potential indication like Dermatomyositis, Polymyositis, Spondylarthritis, Vasculitis, and Atopic dermatitis in the 7MM. A detailed picture of STELARA's existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the STELARA for approved and potential indications. The STELARA market report provides insights about STELARA's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current STELARA performance, future market assessments inclusive of the STELARA market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of STELARA sales forecasts, along with factors driving its market.

STELARA Drug Summary

STELARA is a fully human monoclonal antibody developed by Johnson & Johnson that is approved for the treatment of several immune-mediated inflammatory diseases, including plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. The drug works by selectively binding to the p40 protein subunit shared by interleukin-12 (IL-12) and interleukin-23 (IL-23), thereby inhibiting downstream inflammatory pathways involved in chronic immune activation. STELARA is administered as a subcutaneous injection for most indications, while patients with inflammatory bowel disease receive an initial intravenous induction dose followed by subcutaneous maintenance therapy every 8 to 12 weeks, offering a convenient long-interval dosing regimen. Clinical studies such as UNITI, IM-UNITI, and UNIFI demonstrated significant efficacy in inducing and maintaining clinical remission, mucosal healing, and symptom improvement in Crohn's disease and ulcerative colitis, including in patients previously treated with biologics. The therapy is widely recognized for its durable efficacy, broad label coverage, and favorable safety profile, with common adverse effects including nasopharyngitis, headache, fatigue, injection-site reactions, and increased susceptibility to infections, while patients are monitored for serious infections, malignancies, and hypersensitivity reactions during treatment. The report provides STELARA's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the STELARA Market Report

The report provides insights into:

• A comprehensive product overview including the STELARA MoA, description, dosage and administration, research and development activities in approved indications like Crohn's disease, Plaque psoriasis, Psoriasis, Psoriatic arthritis, and Ulcerative colitis; as well as potential indication like Dermatomyositis, Polymyositis, Spondylarthritis, Vasculitis, and Atopic dermatitis.
• Elaborated details on STELARA regulatory milestones and other development activities have been provided in STELARA market report.
• The report also highlights STELARA's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The STELARA market report also covers the patents information, generic entry and impact on cost cut.
• The STELARA market report contains current and forecasted STELARA sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The STELARA market report also features the SWOT analysis with analyst views for STELARA in approved and potential indications.

Methodology:

The STELARA market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

STELARA Analytical Perspective by DelveInsight

• In-depth STELARA Market Assessment

This STELARA sales market forecast report provides a detailed market assessment of STELARA for approved indication like Crohn's disease, Plaque psoriasis, Psoriasis, Psoriatic arthritis, and Ulcerative colitis; as well as potential indication like Dermatomyositis, Polymyositis, Spondylarthritis, Vasculitis, and Atopic dermatitis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted STELARA sales data uptil 2034.

• STELARA Clinical Assessment

The STELARA market report provides the clinical trials information of STELARA for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

STELARA Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

STELARA Market Potential & Revenue Forecast

• Projected market size for the STELARA and its key indications
• Estimated STELARA sales potential (STELARA peak sales forecasts)
• STELARA Pricing strategies and reimbursement landscape

STELARA Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• STELARA Market positioning compared to existing treatments
• STELARA Strengths & weaknesses relative to competitors

STELARA Regulatory & Commercial Milestones

• STELARA Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

STELARA Clinical Differentiation

• STELARA Efficacy & safety advantages over existing drugs
• STELARA Unique selling points

STELARA Market Report Highlights

• In the coming years, the STELARA market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The STELARA companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence STELARA's dominance.
• Other emerging products for Crohn's disease, Plaque psoriasis, Psoriasis, Psoriatic arthritis, and Ulcerative colitis; as well as potential indication like Dermatomyositis, Polymyositis, Spondylarthritis, Vasculitis, and Atopic dermatitis are expected to give tough market competition to STELARA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of STELARA in approved and potential indications.
• Analyse STELARA cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted STELARA sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of STELARA in approved and potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of STELARA? How strong is STELARA's clinical and commercial performance?
• What is STELARA's clinical trial status in each individual indications such as Crohn's disease, Plaque psoriasis, Psoriasis, Psoriatic arthritis, and Ulcerative colitis; as well as potential indication like Dermatomyositis, Polymyositis, Spondylarthritis, Vasculitis, and Atopic dermatitis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the STELARA Manufacturers?
• What are the key designations that have been granted to STELARA for approved and potential indications? How are they going to impact STELARA's penetration in various geographies?
• What is the current and forecasted STELARA market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of STELARA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to STELARA for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is STELARA? What is the duration of therapy and what are the geographical variations in cost per patient?